Full Text
EE500 Cost-Utility Analysis of Dupilumab Versus Omalizumab in the Treatment of Severe Asthma in China

Abstract

Authors

Nuoming Xu Xinyue Jiang Xiaoning He

Back to Volume 28, Supplemental Issue 6S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×